{"id":"NCT02058147","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","officialTitle":"A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2014-02-07","resultsPosted":"2017-02-10","lastUpdate":"2017-05-09"},"enrollment":1170,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Insulin glargine/lixisenatide Fixed Ratio Combination","otherNames":["(HOE901/AVE0010)"]},{"type":"DRUG","name":"Insulin glargine (HOE901)","otherNames":["Lantus"]},{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":["Lyxumia"]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)","type":"EXPERIMENTAL"},{"label":"Insulin Glargine","type":"ACTIVE_COMPARATOR"},{"label":"Lixisenatide","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to Week 30.\n\nSecondary Objective:\n\nTo compare the overall efficacy and safety of insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine alone and to lixisenatide alone (on top of metformin treatment) over a 30 week treatment period in participants with type 2 diabetes.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 30","timeFrame":"Baseline, Week 30","effectByArm":[{"arm":"Insulin Glargine/Lixisenatide Fixed Ratio Combination","deltaMin":-1.63,"sd":0.038},{"arm":"Insulin Glargine","deltaMin":-1.34,"sd":0.039},{"arm":"Lixisenatide","deltaMin":-0.85,"sd":0.052}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":16},"locations":{"siteCount":273,"countries":["United States","Australia","Belgium","Canada","Chile","Czechia","Denmark","Estonia","France","Germany","Hungary","Italy","Latvia","Lithuania","Mexico","Poland","Romania","Russia","South Africa","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["27527848","35101326","31124299","31114694","30550345","29974618","29923298","28432746"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":469},"commonTop":["Nausea","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis","Headache"]}}